Head to Head Survey: Enzo Biochem (NYSE:ENZ) vs. Castle Biosciences (NYSE:CSTL)

Enzo Biochem (NYSE:ENZ) and Castle Biosciences (NASDAQ:CSTL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, earnings and institutional ownership.

Profitability

This table compares Enzo Biochem and Castle Biosciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enzo Biochem 3.07% -33.03% -26.37%
Castle Biosciences N/A N/A N/A

Earnings & Valuation

This table compares Enzo Biochem and Castle Biosciences’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Enzo Biochem $81.17 million 1.77 $2.49 million N/A N/A
Castle Biosciences N/A N/A N/A N/A N/A

Enzo Biochem has higher revenue and earnings than Castle Biosciences.

Analyst Ratings

This is a summary of recent recommendations and price targets for Enzo Biochem and Castle Biosciences, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enzo Biochem 0 0 0 0 N/A
Castle Biosciences 0 0 5 0 3.00

Castle Biosciences has a consensus target price of $31.60, suggesting a potential upside of 43.12%. Given Castle Biosciences’ higher probable upside, analysts plainly believe Castle Biosciences is more favorable than Enzo Biochem.

Institutional & Insider Ownership

68.5% of Enzo Biochem shares are held by institutional investors. Comparatively, 0.9% of Castle Biosciences shares are held by institutional investors. 9.4% of Enzo Biochem shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

About Enzo Biochem

Enzo Biochem, Inc., an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis to life science researchers. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication levels, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of approximately 30 patient service centers in New York and New Jersey; and a free standing ‘STAT' or rapid response laboratory in New York City, as well as a full-service phlebotomy department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The company markets its products and services through its direct sales force and a network of distributors in the United States and internationally. Enzo Biochem, Inc. was founded in 1976 and is headquartered in New York, New York.

About Castle Biosciences

Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.

Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply